Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
twitter
facebook
linkedin
Investors
Press Releases
NASDAQ: ENVB
Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Press Releases
Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds
December 2, 2024
Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior
November 25, 2024
Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results
November 14, 2024
Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002
November 12, 2024
Enveric Biosciences Announces Broad Range of Patent Issuances
November 4, 2024
Enveric Biosciences Announces Broad Range of Patent Issuances
November 4, 2024
Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003
October 15, 2024
Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop
September 26, 2024
Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit
September 25, 2024
Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 4, 2024
1
2
3
…
14
›
Close Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
twitter
facebook
linkedin